Translational Session
Changing Landscape for Management of Vasculitis, Including the Robert W. Schrier, MD, Endowed Lectureship
November 07, 2025 | 10:30 AM - 12:30 PM
Location: General Assembly A, Convention Center
Session Description
This session provides an update on key treatment changes in ANCA-associated vasculitis, discusses the international development of a strategy to study treatments in IgA vasculitis, and reviews the approach to assessment and management of cryoglobulinemic vasculitis.
Note: Continuing education credits are not being offered for this session.
ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Schrier Endowed Lectureship.
ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Dimitrios Goumenos.
Learning Objective(s)
- Describe current KDIGO recommendations and future approaches to B cell depletion and modulation in ANCA-associated vasculitis
- Summarize the evidence for plasma exchange and the current KDIGO guideline recommendation regarding plasma exchange in ANCA-associated vasculitis
- Summarize the evidence for treatment of IgA vasculitis and describe the current unmet needs and the role of an international consortium to address these gaps
- Discuss comprehensive updates on the assessment and treatment of cryoglobulinemic vasculitis
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
- ANCA-Associated Vasculitis: Lessons Learned from Patients in Long-Term Remission off Therapy: The Robert W. Schrier, MD, Endowed Lectureship
10:30 AM - 11:00 AM
- Is There Still a Role for Plasma Exchange in ANCA-Associated Vasculitis?
11:00 AM - 11:30 AM
- How Do We Improve Outcomes in IgA Vasculitis?
11:30 AM - 12:00 PM
- Cryoglobulinemia and Cryoglobulinemic Vasculitis
12:00 PM - 12:30 PM